Skip to content


Zavesca (miglustat) is a small molecule pharmaceutical. Miglustat was first approved as Zavesca on 2002-11-20. It is used to treat gaucher disease in the USA. It has been approved in Europe to treat gaucher disease and niemann-pick diseases. The pharmaceutical is active against ceramide glucosyltransferase. In addition, it is known to target lysosomal acid glucosylceramidase.
Trade Name Zavesca
Common Name Miglustat
Indication gaucher disease, niemann-pick diseases
Drug Class Enzyme inhibitors: glucosyltransferase inhibitors
Get full access now